COMMUNIQUÉS West-GlobeNewswire

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

28/02/2025 - 15:14

All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of [...]

Orion Corporation: Managers’ transactions – Niclas Lindstedt

28/02/2025 - 16:00

ORION CORPORATION MANAGERS’ TRANSACTIONS 28 FEBRUARY 2025 at 17.00 EET Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

28/02/2025 - 16:34

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Spectral AI, Inc. (NASDAQ: MDAI), the reporting date of the financial results for the fourth quarter was incorrectly [...]

SRx Health Solutions Granted Final Order to Proceed with the Acquisition by Better Choice Company

28/02/2025 - 16:41

TAMPA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced today that SRx Health Solutions, Inc. (“ [...]

Orion Corporation: Managers’ transactions – Outi Vaarala

28/02/2025 - 16:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 28 FEBRUARY 2025 at 17.45 EET Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

28/02/2025 - 17:14

First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX [...]

Valneva reçoit un avis positif du CHMP de l’EMA pour élargir l’indication de son vaccin contre le chikungunya IXCHIQ® aux adolescents

28/02/2025 - 17:45

Si l’avis est validé par la Commission Européenne, IXCHIQ ® pourrait devenir le premier vaccin contre le chikungunya disponible en Europe pour les adolescents âgés de 12 ans et plus Saint Herblain (France), le 28 [...]

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

28/02/2025 - 17:45

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – Valneva SE (Nasdaq: [...]

Groupe PAT : Hausse du Chiffre d’Affaires Combiné 2024

28/02/2025 - 18:30

Vandœuvre-lès-Nancy, le 28 février 2025 - 18 : 30 (CET) Communiqué de presse Pour diffusion immédiate Hausse du Chiffre d’Affaires Combiné 2024 Chiffre d’affaires combiné non audité en progression à 2,9 M€ (+26%/2023) [...]

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

28/02/2025 - 19:17

Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies. The company’s ExacTcell™ technology enabled a proof-of-concept trial with highly positive results, published in Blood [...]

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28/02/2025 - 22:00

REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting [...]

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

28/02/2025 - 22:00

Webcast to be held Monday, March 3rd at 8:30 a.m. ET SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel [...]

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

28/02/2025 - 22:00

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the [...]

Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders

28/02/2025 - 22:01

Meeting adjourned to Wednesday, March 5, 2025 at 9:30 a.m. Mountain Time BROOMFIELD, Colo., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ: ACON) (NASDAQ: ACONW), a healthcare [...]

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

28/02/2025 - 22:04

Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% [...]

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

28/02/2025 - 22:04

Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

28/02/2025 - 22:05

SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger [...]

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

28/02/2025 - 22:05

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued [...]

Alignment Healthcare Reports Fourth Quarter and Full-Year 2024 Results; Provides Full-Year 2025 Financial Guidance

27/02/2025 - 22:01

Reports 189,100 health plan members as of Dec. 31, 2024, up 58.6% year-over-year, beating year-end expectations Achieves first full year of positive adjusted EBITDA as a public company, driven by operating leverage and [...]